Sociedad Paraguaya De Diabetologia

EL 1 DE ABRIL LA FDA APROBÓ EL USO DE ORFORGLIPRON PARA EL TRATAMIENTO DE LA OBESIDAD Bajo el nombre comercial de Foundayo, el orforglipron es una molécula pequeña de naturaleza no peptídica (C48H48F2N10O5) que actúa como agonista del receptor de GLP-1.

🎯Los SGLT2i no solo bajan glucosa. ✍️También reducen la lesión renal aguda 21–34%, mejoran la hemodinámica renal y reducen el estrés celular 👇@SENefrologia @SOMANEorg

𝗧𝗵𝗲 𝗘𝗳𝗳𝗲𝗰𝘁 𝗼𝗳 𝗚𝗟𝗣-𝟭 𝗥𝗲𝗰𝗲𝗽𝘁𝗼𝗿 𝗔𝗴𝗼𝗻𝗶𝘀𝘁𝘀 𝗼𝗻 𝗚𝗹𝘆𝗰𝗮𝘁𝗲𝗱 𝗛𝗲𝗺𝗼𝗴𝗹𝗼𝗯𝗶𝗻 𝗟𝗲𝘃𝗲𝗹𝘀 Randomized, placebo-controlled trials of the glucagon-like peptide-1 (GLP-1) receptor agonists have provided strong evidence to support their use — in fact, they have presaged a mini-revolution in how type 2 diabetes is managed. 👉 nejm.org/doi/full/10.10… Tirzepatide was the first dual GLP-1 and glucose-dependent insulinotropic peptide receptor agonist approved for the treatment of type 2 diabetes on the basis of the SURPASS-1 (Tirzepatide [LY3298176] in Participants with Type 2 Diabetes Not Controlled with Diet and Exercise Alone) trial, a randomized, placebo-controlled trial of tirzepatide (administered in weekly doses of 5 mg, 10 mg, or 15 mg) paired with metformin for treatment of type 2 diabetes (seen in figure). Tirzepatide reduced glycated hemoglobin levels by as much as 2 percentage points and was superior to placebo at all dose levels. At 40 weeks, nearly 90% of participants had glycated hemoglobin levels of less than 7.0%, a change that was associated with profound weight loss. Read the Review Article “GLP-1 Receptor Agonists” by Clifford J. Rosen, MD, and Julie R. Ingelfinger, MD, from @TuftsMedSchool and the Maine Medical Center Institute for Research: nejm.org/doi/full/10.10…

For readers interested in GLP-1-based therapies for obesity and beyond, here's a comprehensive review nature.com/articles/s4157… rdcu.be/fbrIE

La inteligencia artificial no es el futuro: es el presente. 🤖La IA ya está en la educación, aunque muchas veces no lo notamos. 💡 Puede ayudarte a planificar clases, generar ideas, estructurar contenidos, optimizar tiempos. 🧠 Puede mejorar la personalización del aprendizaje y adaptar contenidos según necesidades. 📊 Puede apoyar la evaluación (Automatización, análisis y seguimiento). 🤝 Puede fortalecer el rol tutorial. Más tiempo para acompañar, menos carga operativa. El desafío no es evitarla, sino aprender a usarla con sentido pedagógico. En este curso vas a descubrir cómo integrarla en tu práctica docente de forma estratégica. 🚀 De la incertidumbre a la oportunidad. 👉 Súmate a nuestro curso en docencia.slanh.net

NUTRIREA-3 Trial: 25 kcal/kg/día y 1,0 a 1,3 g de proteína/ kg/dia comparado con 6 kcal/ kg por día y 0,2 a 0,4 g de proteina/kg/dia), generan más estancia en UCI y más complicaciones... #menospuedesermás nejm.org/doi/full/10.10…

Tirzepatide and Acute Pancreatitis: Does Higher Dose Mean Higher Risk? 🔹 Take-home message first: Current randomized trial evidence does not support a dose-dependent increase in acute pancreatitis risk with tirzepatide across 5 mg, 10 mg, and 15 mg once weekly. Clinical Pearls 1) Acute pancreatitis with tirzepatide appears to be very uncommon. Across 19 RCTs involving 15,471 participants, the overall pancreatitis event rate was only 0.22%, indicating that pancreatitis is a rare event in trial settings. 2) Higher tirzepatide doses did not show a higher pancreatitis signal. There was no statistically significant excess risk when comparing: 10 mg vs 5 mg 15 mg vs 5 mg 15 mg vs 10 mg This is clinically reassuring when escalating dose for glycaemic or obesity benefit. 3) This analysis weakens the common fear that “more incretin effect = more pancreatitis.” At least from available RCT data, dose escalation from 5 to 15 mg did not translate into a measurable pancreatitis gradient. 4) But rarity is not the same as impossibility. Because pancreatitis events were very few, the meta-analysis has limited precision. In simple words: no clear risk signal was seen, but very small differences could still be missed. 5) Trial data may underestimate real-world risk. Most RCTs had short-to-moderate follow-up, were industry funded, and often exclude very high-risk patients. So this evidence is reassuring, but not the final word for long-term routine practice. 6) Dose choice should still be driven by benefit, not fear alone. If a patient needs escalation from 5 → 10 → 15 mg for HbA1c, weight loss, or cardiometabolic targets, pancreatitis concern alone should not automatically prevent uptitration in an otherwise appropriate candidate. 7) What matters more clinically is patient selection. Before starting tirzepatide, actively review baseline pancreatitis risk factors, especially: Gallstones / biliary disease Hypertriglyceridemia Alcohol excess Prior pancreatitis Pancreatic structural disease These may matter more than the actual tirzepatide dose. 8) If abdominal pain occurs, do not dismiss it as “just GI intolerance.” Tirzepatide commonly causes nausea, bloating, fullness, reflux, and dyspepsia, but persistent severe epigastric pain radiating to the back, vomiting, or marked tenderness should trigger evaluation for pancreatitis. 9) Do not over-order amylase/lipase in asymptomatic patients. Routine enzyme monitoring in all patients on tirzepatide is not evidence-based. Instead, focus on clinical vigilance and risk stratification. 10) The practical message for Indian clinicians: Tirzepatide can generally be used with confidence, but with good metabolic housekeeping—control triglycerides, look for gallbladder disease, review alcohol use, and counsel patients clearly about warning symptoms. CME INDIA Bottom Line Bottom Line Tirzepatide-associated acute pancreatitis is rare, and current RCT evidence does not show a dose–response signal between 5, 10, and 15 mg. So in most patients, dose escalation should be guided by efficacy and tolerability—not by an assumed pancreatitis gradient. One-line Clinical Practice Pearl “With tirzepatide, pancreatitis vigilance is essential—but current evidence suggests the patient’s risk profile matters more than the dose itself.” sciencedirect.com/science/articl…

El tren se mueve

Para la opinión pública

I'm sharing with you our first manuscript of 2026. The title is Inflammatory and lipotoxicity mechanisms in obesity related CKD . Link : …blic-pages-files-2025.frontiersin.org/journals/nephr…. @SLANH_ @asocolnefmedios @SLANHJoven @SPyDiabetes @PepaSolerR #CKD #lipotoxiciity.

Francisco Tinahones: ''La obesidad conlleva diabetes, hipertensión y más de 200 patologías'' malagahoy.es/malaga/francis…

Excelente . Allá nos vemos . Muchas gracias por la invitación . @SPyDiabetes .

Lanzamiento del IV Congreso Paraguayo de Diabetes y Enfermedades Cardiometabolica @jorgericof @idfsaca_ @SociedadSeedo

¿Recuerdas cuándo te uniste a X? ¡Yo sí! #MiAniversarioDeX

¿Recuerdas cuándo te uniste a X? ¡Yo sí! #MiAniversarioDeX

«Es fundamental considerar al sujeto con obesidad como un enfermo más» #vca=fixed-btn&vso=eldiariosur&vmc=unknow&vli=malaga" target="_blank" rel="nofollow noopener">diariosur.es/malaga/fundame…

Big fan of the #hypothalamus. Love this area that controls my #hormones thirst, hunger, my emotional instability…

Todo lo que quisiste saber sobre composición corporal y no tea atreviste a preguntar. Magnífica revisión por Carla Prado y Steven B Heymsfield @SociedadSeedo @sociedadSEEN lnkd.in/euySpGVU

@AM_1080 @ABCDigital @nanduti @LaNacionPy @SomosGEN @UltimaHoracom @aticastillo68 @IPSParaguay @mspybs

XVII Congreso Paraguayo de Medicina Interna. Taller de Diabesidad. Cambiando paradigmas @InternaLuque @SociedadSeedo @CristobMorales @DrTinahones @albertlecube @SPyDiabetes @idfsaca_